International Psoriasis Council

Advancing Knowledge. Improving Care.

Advancing Knowledge. Improving Care.

SPEVIGO® Receives Approval for Expanded Indications in China and the United States

Boehringer Ingelheim announced earlier this month that the U.S. Food and Drug Administration (FDA) has approved SPEVIGO® (spesolimab-sbzo) for the treatment of generalized pustular psoriasis (GPP) in adults and pediatric patients aged 12 and above. SPEVIGO® has also expanded approval for use in China, marking approval in 48 countries. 

Boehringer Logo

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.


Recent Posts

IPC Joins IFPA to Mark the Tenth Anniversary of the World Health Assembly Resolution on Psoriasis

Focus on Psoriasis: A Report from the 2024 American Academy of Dermatology (AAD) Annual Meeting

Psoriasis in Older Patients: Epidemiology, Clinical Features, and Treatment Discussion

Also Read

Subscribe to the IPC Newsletter

Stay up-to-date on the latest research, news, and upcoming events right in your inbox.